Certara, Inc. (CERT) - What Are Analysts Saying About This Stock?

Key Points

• Analysts rate Certara a consensus “Hold”: Of 13 firms covering the stock, seven recommend Hold, five recommend Buy or Strong Buy, and one recommends Sell. The average one-year price target is $9.92.
• Certara’s latest quarterly revenue of $94.9 million exceeded analyst estimates, and EPS matched consensus at $0.09; however, revenue fell 9.3% year over year.
• Institutional investors own about 74% of Certara’s shares, and the stock recently traded at $11.57, above its 50-day and 200-day moving averages.

Certara, Inc. (NASDAQ:CERT - Get Free Report) has earned a consensus recommendation of "Hold" from the thirteen research firms that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $9.92.

Several brokerages have weighed in on CERT. Jefferies Financial Group reaffirmed a "hold" rating and set a $12.00 price target on shares of Certara in a report on Friday, November 6th. KeyCorp increased their price objective on shares of Certara from $9.00 to $12.00 and gave the stock an "overweight" rating in a research note on Friday, October 16th. UBS Group restated a "neutral" rating and set a $13.00 price objective on shares of Certara in a research report on Friday, November 6th. Barclays lifted their target price on shares of Certara from $9.00 to $12.00 and gave the company an "equal weight" rating in a research note on Friday, November 6th. Finally, TD Cowen upped their target price on shares of Certara from $9.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, October 13th.

Institutional Investors Weigh In On Certara

Institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Certara in the second quarter worth about $123,259,000. Dimensional Fund Advisors LP raised its stake in Certara by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company's stock valued at $48,806,000 after purchasing an additional 175,024 shares during the period. Haveli Investment Management LLC bought a new stake in Certara during the 2nd quarter valued at approximately $48,470,000. Jefferies Financial Group Inc. bought a new stake in Certara during the 2nd quarter valued at approximately $46,446,000. Finally, Royce & Associates LP lifted its holdings in Certara by 6.6% in the 3rd quarter. Royce & Associates LP now owns 2,937,683 shares of the company's stock worth $27,027,000 after purchasing an additional 181,657 shares in the last quarter. 73.96% of the stock is owned by institutional investors.

Certara Stock Performance

NASDAQ:CERT traded down $0.33 during mid-day trading on Friday, hitting $11.57. 2,668,404 shares of the company traded hands, compared to its average volume of 2,723,653. The company has a quick ratio of 2.58, a current ratio of 2.58 and a debt-to-equity ratio of 0.29. The stock's fifty day moving average price is $9.70 and its 200-day moving average price is $7.40. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -27.55 and a beta of 1.30. Certara has a one year low of $4.45 and a one year high of $12.61.

Certara (NASDAQ:CERT - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09. Certara had a positive return on equity of 3.36% and a negative net margin of 16.14%. The firm had revenue of $94.90 million for the quarter, compared to the consensus estimate of $92.01 million. During the same quarter last year, the company earned $0.14 earnings per share. The business's revenue for the quarter was down 9.3% compared to the same quarter last year. Certara has set its FY 2026 guidance at 0.310-0.340 EPS. Research analysts anticipate that Certara will post 0.21 earnings per share for the current fiscal year.

Certara Company Profile

Certara provides software and consulting services that support the development and use of medicines. Its biosimulation tools help pharmaceutical and biotechnology companies model how drugs behave in the body, assess potential treatment outcomes, and inform decisions during drug research and development. The company's offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial simulation, and drug development analysis. Certara also provides scientific and regulatory consulting, including support for regulatory submissions and strategies that use modeling and simulation to guide development programs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.